Astrazeneca: Pharma giant splashes the cash to settle two legal claims October 3, 2023 Pharma giant AstraZeneca has agreed to pay out $425m in a settlement today after facing multiple claims from litigators that two of its stomach acid drugs caused kidney injuries.
AstraZeneca: Revenue boost despite welcome end of Covid-19 jab sales July 28, 2023 Britain’s biggest FTSE firm AstraZeneca reported an uptick in sales as oncology treatments helped pick up the slack from falling sales of Covid-19 medicines. The pharmaceutical company made over $22.2bn (£17.3bn) – a four per cent increase – during the first half of 2023, causing shares to spring over three per cent on market open [...]
Bosses from Natwest, Shell and Sainsbury’s join PM’s new taskforce to boost growth July 18, 2023 Top bosses from firms including Barclays, Aviva and Shell have joined the Prime Minister’s new business council aimed at supercharging the UK’s growth. Prime Minister Rishi Sunak will chair the first business council meeting at No10 today, followed by a glitzy reception for scores of industry bigwigs to celebrate UK enterprise. CEOs including Alison Rose [...]
AstraZeneca: Britain’s biggest FTSE firm drafts plans to spin off Chinese business – reports June 19, 2023 AstraZeneca, London’s biggest listed company, is looking at plans to spin off its Chinese businesses to protect it from geopolitical tension, according to a report. Citing people familiar with the situation, the Financial Times said the British-Swedish drugs giant has been in talks with bankers for several months. When contacted by the PA news [...]
AstraZeneca: Cancer medicine sales offset a post-pandemic slump in Covid drugs April 27, 2023 AstraZeneca reported a slight dip in sales but beat forecasts on the back of a boost in sales of oncology medicines. The pharmaceutical company reported a 4 per cent fall in revenue to $10.9bn (£8.7bn) on Thursday morning. Sales of oncology drugs helped compensate for a $1.5bn (£1.2bhn) fall in Covid-19 medicines, the company said. [...]
CBI exodus: Which firms have quit or suspended their relationship with the lobby group? April 21, 2023 A slew of top firms have quit or suspended engagement with the CBI today after the lobby group was rocked by new allegations of sexual abuse.
AstraZeneca: UK-Swedish pharma giant almost doubled exports to Russia after invasion of Ukraine March 7, 2023 Anglo-Swedish drugs giant AstraZeneca nearly doubled its exports from Sweden to Russia after the Kremlin launched its full-scale attack on Ukraine, according to a report. Sveriges Radio (SR) – the country’s public service broadcaster – said that the FTSE 100 company had exported 2.2 billion Swedish krona (£174 million) worth of chemicals to Russia from [...]
UK lost out on £320m AstraZeneca factory: Hunt ‘disappointed’ after drug giant choses low-tax Ireland instead February 10, 2023 Chancellor Jeremy Hunt said he was disappointed the UK “lost out this time” on a £320 million new AstraZeneca factory after the drugs giant chose the low-tax Republic of Ireland instead. The group had wanted to build a plant near its existing sites close to Macclesfield, Cheshire, but the “discouraging” tax rate had prompted a [...]
Astrazeneca’s shares rise, as cancer drug uptake offsets fall in sales of pharma giant’s Covid-19 vaccine February 9, 2023 Astrazeneca has posted what it claimed were “strong” financial results for the full year 2022 as surging demand for cancer medicines offset a fall in Covid vaccine revenues. Shares in Astrazeneca jumped on the news as the firm said it expects another year of double-digit revenue growth in 2023. The British firm’s strong results came [...]
Drug developer files patents for cancer treatment which ‘outperforms’ AstraZeneca offering December 20, 2022 Drug development company Nuformix has reformulated and improved one of AstraZeneca’s top cancer drugs, piquing investor interest today. Shares in the London-listed firm jumped nearly a quarter to 35p per share by early afternoon on Tuesday. Nuformix, which focuses on fibrosis and cancer drug repurposing, announced that the drug, known as Olaparib, had “outperformed” AstraZeneca’s [...]